Orion Oyj's latest marketcap:
As of 06/30/2025, Orion Oyj's market capitalization has reached $10.44 B. According to our data, Orion Oyj is the 1871th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | $10.44 B |
| Revenue (ttm) | $1.86 B |
| Net Income (ttm) | $407.08 M |
| Shares Out | 140.69 M |
| EPS (ttm) | $2.9 |
| Forward PE | 22.64 |
| Ex-Dividend Date | 10/15/2025 |
| Earnings Date | 07/18/2025 |
Orion Oyj's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/30/2025 | €10.44 B | 48.35% | 1871 |
| 12/30/2024 | €6 B | 8.99% | 2523 |
| 12/29/2023 | €5.51 B | -23.26% | 2457 |
| 12/30/2022 | €7.18 B | 40.25% | 1860 |
| 12/30/2021 | €5.12 B | -2.82% | 2834 |
| 12/30/2020 | €5.27 B | -8.98% | 2335 |
| 12/30/2019 | €5.79 B | 35.8% | 1935 |
| 12/28/2018 | €4.26 B | -3.29% | 2059 |
| 12/29/2017 | €4.41 B | -25.88% | 2240 |
| 12/30/2016 | €5.94 B | 32.18% | 1577 |
Company Profile
About Orion Oyj
Orion Oyj is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Headquartered in Espoo, Finland, the company operates globally, serving markets in Scandinavia, Europe, North America, and beyond.
Key Products & Services
- Human Pharmaceuticals: Includes treatments such as:
- Nubeqa (prostate cancer)
- Entacapone, Stalevo, Comtess, Comtan (Parkinson's disease)
- Burana (inflammatory pain)
- Divina series (menopausal symptoms)
- Simdax (acute decompensated heart failure)
- Fareston (breast cancer)
- Trexan (rheumatoid arthritis and cancer)
- Dexdor, Precedex, Dexmedetomidine (human sedation)
- Asthma & COPD Treatments: Easyhaler product line, including Salmeterol/fluticasone, Budesonide/formoterol, and others.
- Veterinary Drugs: Bonqat, Clevor, Domosedan, Sileo, and Tessie, among others.
- APIs & Contract Manufacturing: Supplies generic compounds and proprietary APIs, along with manufacturing services.
Strategic Collaborations
Orion Oyj has partnered with Invenra to develop bispecific antibody cancer therapeutics and collaborates with Abilita Therapeutics on innovative antibody therapeutics.
Founded: 1917 | Headquarters: Espoo, Finland
Frequently Asked Questions
-
What is Orion Oyj's (HEL-ORNBV) current market cap?As of 06/30/2025, Orion Oyj (including the parent company, if applicable) has an estimated market capitalization of $10.44 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Orion Oyj (HEL-ORNBV) rank globally by market cap?Orion Oyj global market capitalization ranking is approximately 1871 as of 06/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.